PRESS RELEASE published on 03/30/2023 at 23:00, 1 year 7 months ago Biophytis: The Combined General Meeting will be held on second call on April 17, 2023
PRESS RELEASE published on 03/27/2023 at 08:00, 1 year 7 months ago Biophytis: Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Resea
PRESS RELEASE published on 03/17/2023 at 08:00, 1 year 8 months ago Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
PRESS RELEASE published on 03/09/2023 at 08:00, 1 year 8 months ago Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
PRESS RELEASE published on 03/02/2023 at 00:00, 1 year 8 months ago Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-1
PRESS RELEASE published on 02/27/2023 at 08:00, 1 year 8 months ago Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of
PRESS RELEASE published on 02/23/2023 at 08:00, 1 year 8 months ago : Biophytis To Host A Combined General Shareholder’s Meeting On March 30, 2023
PRESS RELEASE published on 02/02/2023 at 08:00, 1 year 9 months ago Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19
PRESS RELEASE published on 01/31/2023 at 08:00, 1 year 9 months ago Biophytis publishes its financial results for the first half of 2022
PRESS RELEASE published on 01/19/2023 at 00:00, 1 year 10 months ago Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd
Published on 11/21/2024 at 22:05, 25 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 40 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 15 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 20 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 2 hours 30 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 3 hours 29 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 3 hours 54 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 4 hours 32 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 4 hours 39 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 4 hours 39 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 15 hours 32 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 4 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 4 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 14 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
